DDInter1311 DDInter593
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.
Norepinephrine {u} (Compound) binds {v} (Gene) ADRA2C
ADRA2C {u} (Gene) is bound by {v} (Compound) Doxepin
Norepinephrine {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Doxepin
Norepinephrine {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Phenylephrine
Phenylephrine {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Norepinephrine {u} (Compound) resembles {v} (Compound) Levonordefrin
Levonordefrin {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Norepinephrine {u} (Compound) binds {v} (Gene) ADRA2C
ADRA2C {u} (Gene) regulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Doxepin
Norepinephrine (Compound) binds ADRA2C (Gene) and ADRA2C (Gene) is bound by Doxepin (Compound)
Norepinephrine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Doxepin (Compound)
Norepinephrine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Doxepin (Compound)
Norepinephrine (Compound) resembles Levodopa (Compound) and Levodopa may cause a minor interaction that can limit clinical effects when taken with Doxepin
Norepinephrine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Doxepin
Norepinephrine (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Norepinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may lead to a major life threatening interaction when taken with Doxepin
Norepinephrine (Compound) resembles Dopamine (Compound) and Dopamine may lead to a major life threatening interaction when taken with Doxepin
Norepinephrine (Compound) resembles Levonordefrin (Compound) and Levonordefrin may lead to a major life threatening interaction when taken with Doxepin
Norepinephrine (Compound) binds ADRA2C (Gene) and ADRA2C (Gene) regulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Doxepin (Compound)